News

Pharma Technology Focus’ digital magazine brings together the latest news from the pharmaceutical industry, as well as offering expert views and analysis from industry insiders to ensure the

Being developed for the treatment of several cancer indications including patients with recurrent glioblastoma, DNX-2401 is claimed to be the most potent and effective oncolytic virus delivered to

Prestalia, which is the first single-pill, fixed-dose combination (FDC) of perindopril arginine and amlodipine besylate, is indicated for the treatment of hypertension in the U.S. Perindopril is a

The investigational, all-oral, interferon-free medicine is primarily indicated for the treatment of adult patients with chronic genotype 1 (GT1) hepatitis C virus (HCV) infection. The three direct-acting antiviral

Soliris (eculizumab) is currently approved for the treatment of patients with paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS). It is not approved in any country

Critical Outcome Technologies president and CEO Dr Wayne Danter said that receiving the Orphan Drug Designation for COTI-2 speaks to the need for new treatment options for patients

OCTAVE is a phase I/II clinical trial to assess the safety and efficacy of its oncolytic vaccine enadenotucirev (previously known as ColoAd1) in platinum-resistant ovarian cancer patients at

These settlements dismiss a pending appeal with the US Court of Appeals for the Federal Circuit of a trial court decision that found the ‘570 patent to be

The Class 1 resubmission follows a complete response letter issued by the FDA that referenced previously observed deficiencies at a Boehringer Ingelheim facility where empagliflozin will be manufactured.